The purpose of this study is to evaluate the activity of oral AB1010, administered at two dose levels during 3 years to patients with primary or secondary progressive multiple sclerosis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
35
change in MSFC
average change in multiple sclerosis functional composite (MSFC) score relative to baseline, with clinical response defined as a \> 100% improvement (increase) from baseline
Time frame: 12 months
MSFC subcategories
timed 25-foot walk (T25FW)
Time frame: 12 months
Expanded Disability Status Scale (EDSS)
Time frame: 12 months
MFSC subcategories
9-Hole Peg Test (9-HPT)
Time frame: 12 months
MFSC subcategories
Paced Auditory Addition Test (PASAT-3'')
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.